Conduit Pharmaceuticals Inc. (CDT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Conduit Pharmaceuticals Inc. (CDT:NASDAQ), powered by AI.

Current Price
$4.08
P/E Ratio
-0.0
Market Cap
235,848
Sector
Healthcare
What is the Conduit Pharmaceuticals Inc. stock price forecast?

Conduit Pharmaceuticals Inc. is currently trading at $4.08. View real-time AI analysis on Alpha Lenz.

What is Conduit Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Conduit Pharmaceuticals Inc. on Alpha Lenz.

What is Conduit Pharmaceuticals Inc.'s P/E ratio?

Conduit Pharmaceuticals Inc.'s P/E ratio is -0.0.

Conduit Pharmaceuticals Inc.

NASDAQ · CDT
$4.08
Ask about Conduit Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Conduit Pharmaceuticals Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 491.4%.

Ask for details

Company Overview

Conduit Pharmaceuticals Inc. is an innovative biotechnology company specializing in the development of therapeutic treatments. The primary function of Conduit Pharmaceuticals is to advance clinical phase drug candidates targeting chronic diseases with significant unmet medical needs. Operating within the highly dynamic biotechnology industry, Conduit Pharmaceuticals focuses on leveraging cutting-edge scientific research to create effective therapies that can transform patient care and outcomes. The company's robust research and development pipeline emphasizes novel solutions in disease areas with a high demand for innovative treatments, such as autoimmune disorders and oncology. As a participant in the biotech sector, Conduit Pharmaceuticals plays a pivotal role in addressing critical health challenges, contributing to scientific advancements, and influencing healthcare delivery. By fostering collaborations with research institutions and healthcare entities, it remains at the forefront of transformative drug development, significantly impacting both the pharmaceutical market landscape and patient communities worldwide. With a commitment to scientific excellence and patient-centric innovation, Conduit Pharmaceuticals continues to chart a course aimed at delivering breakthrough therapies poised to meet pressing global health needs.

CEODr. David Joszef Tapolczay
SectorHealthcare
IndustryBiotechnology
Employees7

Company Statistics

FY 2024

Profile

$235.85KMarket Cap
$0.00Revenue
0.00Shares Out
7Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-0.01P/E
-0.03P/B
N/AEV/Sales
-0.47EV/EBITDA
-0.02P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-312.03%ROA
491.37%ROE
-285.64%ROIC

Financial Health

$554.00KCash & Cash Equivalents
$10.43MNet Debt
-161.73%Debt/Equity
N/AInterest Cov
Alpha Chat Insight

Conduit Pharmaceuticals Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 491.4%.

Ask for details

Frequently Asked Questions

Conduit Pharmaceuticals Inc. (ticker: CDT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 7 employees. Market cap is $235,848.

The current price is $4.08 with a P/E ratio of -0.01x and P/B of -0.03x.

ROE is 491.37%.

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Conduit Pharmaceuticals Inc. (Healthcare) Stock Forecast & Analysis $4.08 | Alpha Lenz